Treatment of Advanced Parkinson's Disease in the United States: A Cost-Utility Model

Author： Groenendaal Huybert  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.30, Iss.11, 2010-11, pp. : 789-798

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Treatment of Parkinson's Disease with Entacapone in the United States

By Palmer C.S.  

PharmacoEconomics, Vol. 20, Iss. 9, 2002-09 ,pp. : 617-628

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis: Cost-Utility Analysis Using a Markov Model

By Kreck Simon   Klaus Jochen  

PharmacoEconomics, Vol. 26, Iss. 4, 2008-01 ,pp. : 311-328

Adis International

Access to resources Recommend Favorite

Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn's Disease

By Yu Andrew P.  

PharmacoEconomics, Vol. 27, Iss. 7, 2009-07 ,pp. : 609-621

Adis International

Access to resources Recommend Favorite

Methods for Measuring Temporary Health States for Cost-Utility Analyses

By Wright Davene R.   Wittenberg Eve   Swan J. Shannon   Miksad Rebecca A.   Prosser Lisa A.  

PharmacoEconomics, Vol. 27, Iss. 9, 2009-09 ,pp. : 713-723

Adis International

Access to resources Recommend Favorite

Cost-Utility Analysis of Methadone Maintenance Treatment: A Methodological Approach

By Vanagas Giedrius   Padaiga Zilvinas   Bagdonas Eugenijus  

Substance Use & Misuse, Vol. 41, Iss. 1, 2006-06 ,pp. : 87-101

Informa Healthcare

Access to resources Recommend Favorite